Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | FLT3 exon 14 ins FLT3 F691L |
| Therapy | Nintedanib |
| Indication/Tumor Type | hematologic cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FLT3 exon 14 ins FLT3 F691L | hematologic cancer | sensitive | Nintedanib | Preclinical | Actionable | In a preclinical study, Ofev (nintedanib) inhibited viability with greater potency compared to Nexavar (sorafenib) in cells expressing FLT3-ITD and FLT3 F691L in culture, and demonstrated enhanced suppression of tumor growth and longer survival compared to Xospata (gilteritinib) and Vanflyta (quizartinib) in mouse models (PMID: 42035942). | 42035942 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (42035942) | Nintedanib is a potent FLT3 inhibitor with activity against FLT3-ITD and overcomes the gatekeeper F691L resistance mutation in acute myeloid leukemia. | Full reference... |